Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions.

RATIONALE Percutaneous aortic valve procedures are a major breakthrough in the management of patients with aortic stenosis. Residual gradient and residual aortic regurgitation are major predictors of midterm and long-term outcome after percutaneous aortic valve procedures. We hypothesized that (1) induction/recovery of high molecular weight (HMW) multimers of von Willebrand factor defect could be instantaneous after acute changes in blood flow, (2) a bedside point-of-care assay (platelet function analyzer-closure time adenine DI-phosphate [PFA-CADP]), reflecting HMW multimers changes, could be used to monitor in real-time percutaneous aortic valve procedures. OBJECTIVE To investigate the time course of HMW multimers changes in models and patients with instantaneous induction/reversal of pathological high shear and its related bedside assessment. METHODS AND RESULTS We investigated the time course of the induction/recovery of HMW multimers defects under instantaneous changes in shear stress in an aortic stenosis rabbit model and in patients undergoing implantation of a continuous flow left ventricular assist device. We further investigated the recovery of HMW multimers and monitored these changes with PFA-CADP in aortic stenosis patients undergoing transcatheter aortic valve implantation or balloon valvuloplasty. Experiments in the aortic stenosis rabbit model and in left ventricular assist device patients demonstrated that induction/recovery of HMW multimers occurs within 5 minutes. Transcatheter aortic valve implantation patients experienced an acute decrease in shear stress and a recovery of HMW multimers within minutes of implantation which was sustained overtime. In patients with residual high shear or with residual aortic regurgitation, no recovery of HMW multimers was observed. PFA-CADP profiles mimicked HMW multimers recovery both in transcatheter aortic valve implantation patients without aortic regurgitation (correction) and transcatheter aortic valve implantation patients with aortic regurgitation or balloon valvuloplasty patients (no correction). CONCLUSIONS These results demonstrate that variations in von Willebrand factor multimeric pattern are highly dynamic, occurring within minutes after changes in blood flow. It also demonstrates that PFA-CADP can evaluate in real time the results of transcatheter aortic valve procedures.

[1]  P. Leprince,et al.  Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement Procedures: Analysis of Predictors and Impact on Long-Term Mortality Insights From the FRANCE2 Registry , 2014, Circulation.

[2]  Wei Li,et al.  Hypertensive stretch regulates endothelial exocytosis of Weibel-Palade bodies through VEGF receptor 2 signaling pathways , 2013, Cell Research.

[3]  R. Baliga From clinical observation to mechanism--Heyde's syndrome. , 2013, The New England journal of medicine.

[4]  B. Prendergast,et al.  Standalone balloon aortic valvuloplasty: Indications and outcomes from the UK in the transcatheter valve era , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  Dong Chen,et al.  Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study). , 2013, The American journal of cardiology.

[6]  C. Casari,et al.  von Willebrand factor: the old, the new and the unknown , 2012, Journal of thrombosis and haemostasis : JTH.

[7]  P. Pibarot,et al.  Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. , 2012, JACC. Cardiovascular interventions.

[8]  C. Schlensak,et al.  Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  C. Solomon,et al.  Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery. , 2011, British journal of anaesthesia.

[10]  B. Carabello Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery , 2011, Current cardiology reports.

[11]  K. Kent,et al.  Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients. , 2010, JACC. Cardiovascular interventions.

[12]  M. Slaughter,et al.  Acquired von Willebrand Syndrome in Patients With an Axial Flow Left Ventricular Assist Device , 2010, Circulation. Heart failure.

[13]  N. Uriel,et al.  Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. , 2010, Journal of the American College of Cardiology.

[14]  K. Kent,et al.  COMPLICATIONS AND OUTCOMES OF BALLOON AORTIC VALVULOPLASTY IN HIGH-RISK OR INOPERABLE PATIENTS , 2010 .

[15]  G. Golderer,et al.  Analysis of von Willebrand factor multimers by simultaneous high- and low-resolution vertical SDS-agarose gel electrophoresis and Cy5-labeled antibody high-sensitivity fluorescence detection. , 2010, American journal of clinical pathology.

[16]  Cheng-Zhong Zhang,et al.  Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor , 2009, Science.

[17]  N. Lamblin,et al.  Functional Impairment of Von Willebrand Factor in Hypertrophic Cardiomyopathy: Relation to Rest and Exercise Obstruction , 2008, Circulation.

[18]  Christoph Benk,et al.  Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  M. Cupa,et al.  Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  J. Dong Cleavage of ultra‐large von Willebrand factor by ADAMTS‐13 under flow conditions , 2005, Journal of thrombosis and haemostasis : JTH.

[21]  S. Susen,et al.  Acquired von Willebrand syndrome in aortic stenosis. , 2003, The New England journal of medicine.

[22]  A. Sala,et al.  Proteolysis of von Willebrand Factor and Shear Stress–Induced Platelet Aggregation in Patients With Aortic Valve Stenosis , 2000, Circulation.

[23]  P. V. van Genderen,et al.  Acquired von Willebrand Syndrome: Data from an International Registry , 2000, Thrombosis and Haemostasis.

[24]  A. Jatene,et al.  Reversible pulmonary trunk banding with a balloon catheter: assessment of rapid pulmonary ventricular hypertrophy. , 2000, The Journal of thoracic and cardiovascular surgery.

[25]  É. Fressinaud,et al.  Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. , 1998, Blood.

[26]  R. Nagel,et al.  Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. , 1994, Blood.

[27]  S. Windecker,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[28]  S. Windecker,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, European heart journal.

[29]  W. Keeling,et al.  Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery , 2011 .

[30]  J. Chambers,et al.  Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  P. V. van Genderen,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation , 1999 .